Silodosin

Introduction Overview

Generic Name

silodosin

Brand Name

Rapaflo

Dosage Form

oral capsule (4 mg; 8 mg)

Drug Class

Alpha blockers

Pharmacokinetics

Absorption: Silodosin is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within approximately 2 to 3 hours under fed conditions, as administration with a meal enhances its bioavailability. The absolute bioavailability of silodosin is moderate due to first-pass metabolism in the liver. Food intake does not significantly alter the overall extent of absorption but can decrease peak plasma levels, which may reduce the risk of adverse effects such as hypotension.

Distribution: Silodosin exhibits a high degree of plasma protein binding, estimated at around 97%, primarily to albumin. This extensive protein binding contributes to a relatively low volume of distribution, indicating predominant localization in the plasma rather than extensive tissue sequestration. Distribution into prostatic tissue is notable, facilitating its therapeutic effect in benign prostatic hyperplasia (BPH). The drug’s ability to selectively target alpha-1A adrenergic receptors, mostly located in the lower urinary tract, minimizes systemic side effects.

Metabolism: Silodosin undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP3A4, with some contribution from uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes. The major metabolic pathways include oxidation and glucuronidation, resulting in several inactive metabolites. The involvement of CYP3A4 explains important drug interactions with inhibitors like ketoconazole, itraconazole, and clarithromycin, which can significantly increase silodosin plasma levels.

Elimination: The elimination half-life of silodosin ranges from approximately 11 to 13 hours, allowing for once-daily dosing. The drug is excreted primarily via the urine (approximately 33%) and feces (approximately 54%) primarily as metabolites rather than unchanged drug. Renal impairment can affect elimination, necessitating dose adjustments or contraindications in severe renal or hepatic dysfunction. The drug’s pharmacokinetics allow steady-state concentrations to be achieved generally within 2 to 3 days of repeated dosing.

Dosage Forms

Available Dosage Forms:
Silodosin is available as oral capsules formulated in 4 mg and 8 mg strengths. These capsules are designed for once-daily dosing and can be taken with a meal to improve absorption and tolerability. For patients experiencing difficulty swallowing capsules, the contents of the capsule may be opened and mixed with a tablespoon of cool applesauce to facilitate administration. The applesauce mixture should be consumed immediately without chewing and followed by a glass of water.

Dosages for Adults and Adolescents:
The recommended and usual adult dose for the treatment of benign prostatic hyperplasia (BPH) is 8 mg taken orally once daily with a meal. Dose adjustments may be considered in patients with moderate renal impairment, while silodosin is contraindicated in patients with severe renal or hepatic impairment. The drug is not approved for use in pediatric populations (under 18 years).

Specific Patient Populations:
In patients with moderate renal impairment (creatinine clearance between 30-50 mL/min), clinical judgment for dose adjustment or close monitoring is recommended due to increased systemic exposure. Silodosin is contraindicated in individuals with severe renal impairment (creatinine clearance less than 30 mL/min) and those with severe hepatic impairment due to altered metabolism and elimination leading to increased drug accumulation. It is not indicated for use in women or children, and safety during pregnancy or breastfeeding has not been established.

Mechanism Of Action

Silodosin is a selective alpha-1 adrenergic receptor antagonist that primarily targets the alpha-1A subtype of adrenergic receptors, which are predominantly located in the smooth muscle of the prostate, bladder neck, and urethra. By selectively blocking these receptors, silodosin causes relaxation of smooth muscle in the lower urinary tract, including the prostatic capsule and urethra, thereby reducing urethral resistance and improving urine flow in patients with benign prostatic hyperplasia (BPH).

The drug's high selectivity for the alpha-1A receptor subtype distinguishes it from other less selective alpha blockers, which also antagonize alpha-1B and alpha-1D receptors located in vascular smooth muscle. This selectivity helps minimize systemic vasodilatory effects such as hypotension and dizziness, which are more common with nonselective alpha blockers. Silodosin's affinity for the alpha-1A receptor is approximately 162 times greater than for alpha-1B receptors, enhancing its therapeutic efficacy and tolerability profile.

On a cellular level, silodosin acts by competitively inhibiting norepinephrine binding to alpha-1A adrenergic receptors, preventing receptor activation and subsequent G-protein coupled signal transduction that would normally promote smooth muscle contraction. This blockade reduces intracellular calcium mobilization and myosin light chain phosphorylation, resulting in relaxation of prostatic and bladder neck muscles, which facilitates urine flow.

Clinical studies have demonstrated that silodosin improves lower urinary tract symptoms associated with BPH, including increased peak urinary flow rate and reduced post-void residual volume, thereby improving quality of life. Its pharmacodynamic effects correlate with selective receptor blockade, resulting in fewer cardiovascular side effects compared to other alpha-1 blockers. Comparative trials have shown similar efficacy to tamsulosin but with potentially improved symptom relief and reduced blood pressure effects, though abnormal ejaculation is reported more frequently with silodosin.

Pharmacological Actions

Selective antagonism of alpha-1A adrenergic receptors in prostatic and bladder neck smooth muscle.
Relaxation of lower urinary tract smooth muscle to reduce bladder outlet obstruction.
Improvement of urine flow rates and reduction of urinary symptoms in BPH.
Minimal blockade of vascular alpha-1B receptors, reducing systemic hypotensive effects.
Inhibition of norepinephrine-induced smooth muscle contraction in the prostate.
Modulation of intracellular calcium signaling pathways leading to muscle relaxation.
Reduction of urethral resistance and detrusor muscle workload.
Improvement of bladder emptying and reduction in postvoid residual urine volume.
Selective receptor targeting reducing incidence of orthostatic hypotension.
Limited effect on blood pressure at therapeutic doses compared to nonselective alpha blockers.
Influences sympathetic nervous system tone localized to lower urinary tract.
Potential alteration of ejaculatory function due to smooth muscle relaxation of the vas deferens.
Facilitation of urinary symptom relief without significant CNS penetration.
Prolonged receptor occupancy aligning with once-daily dosing regimen.
Pharmacodynamic effects linked to improved patient-reported symptom scores and quality of life.

Therapeutic Or Clinical Uses

Treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Improvement of urinary flow in men with enlarged prostate causing obstruction.
Management of symptoms such as urinary hesitancy, weak stream, and incomplete bladder emptying.
Relief of bladder outlet obstruction by relaxing prostatic and bladder neck smooth muscle.
Adjunctive therapy in men with BPH who have intolerance or contraindications to other alpha blockers.
Potential use in patients with moderate renal impairment with dosage adjustment.
Alternative to less selective alpha blockers to minimize hypotensive side effects.
Utility in patients experiencing adverse effects on blood pressure with other alpha-1 antagonists.
Symptomatic treatment improving quality of life in men with BPH.
Reduction in postoperative urinary retention risk related to prostatic obstruction.
Off-label use under clinical discretion for urinary difficulties related to bladder neck dysfunction.
Supportive management in conjunction with other BPH treatments, such as 5-alpha reductase inhibitors.
Treatment option for men not suitable for surgical intervention for BPH.
Improvement in International Prostate Symptom Score (IPSS) and other validated symptom scales.
Potential use in patients where vascular hypotension is a concern due to receptor selectivity.

Side Or Adverse Effects

Dizziness and lightheadedness, especially upon standing (orthostatic hypotension).
Headache of varying intensity reported in clinical use.
Diarrhea as a gastrointestinal side effect.
Abnormal ejaculation, including retrograde ejaculation or decreased volume.
Nasal congestion and sinus discomfort due to vasodilation of nasal mucosa vessels.
Fatigue and asthenia in some patients.
Hypotension symptoms such as fainting, particularly at treatment initiation.
Symptoms of allergic reactions including rash, pruritus, or swelling (rare).
Potential exacerbation of existing low blood pressure conditions.
Rare reports of dizziness severe enough to cause falls in elderly populations.
Transient palpitations or tachycardia in sensitive patients.
Occasional urinary tract infections reported during treatment.
Visual disturbances or blurred vision reported anecdotally but uncommon.
Edema or peripheral swelling in a limited subset of patients.
Gastrointestinal effects such as nausea and abdominal pain reported rarely.

Precautions

Use with caution in patients with a history of low blood pressure or orthostatic hypotension.
Monitor blood pressure regularly, especially during the initial treatment period.
Careful administration in patients with moderate renal impairment; contraindicated in severe impairment.
Avoid use in patients with severe hepatic dysfunction due to metabolism concerns.
Not recommended for use in women or pediatric patients; safety in pregnancy and lactation unknown.
Patients undergoing cataract or other eye surgery should inform the surgeon of silodosin use due to risk of Intraoperative Floppy Iris Syndrome (IFIS).
Exercise caution when used concomitantly with other alpha blockers or antihypertensives.
Inform patients about possible dizziness and advise caution when rising from sitting or lying positions.
Assess prostate specific antigen (PSA) levels prior to initiation to exclude prostate cancer.
Advise patients to avoid activities requiring mental alertness until drug effects are known.
Use caution in patients on low-salt diets or in use of diuretics as volume depletion may exacerbate hypotension.
Consider drug interactions causing elevated silodosin plasma levels via CYP3A4 inhibition.
Adjust dose or discontinue if severe hypotension or adverse cardiovascular effects occur.
Regular follow-up assessments recommended to evaluate symptom improvement and side effects.
Avoid sudden discontinuation without medical supervision to prevent rebound urinary symptoms.

Warnings

Contraindicated in patients with known hypersensitivity to silodosin or components of the formulation.
Not to be used in patients with severe hepatic or severe renal impairment.
Risk of orthostatic hypotension, syncope, and dizziness especially after the first dose.
Potential for intraoperative floppy iris syndrome during cataract surgery in patients with previous or current silodosin use.
Use caution when co-administered with potent CYP3A4 inhibitors such as ketoconazole or clarithromycin to avoid toxic plasma levels.
Avoid use with other alpha blockers or antihypertensives without careful monitoring.
May impair ability to drive or operate machinery due to dizziness or hypotension.
Risk of abnormal ejaculation which can affect sexual function and should be discussed prior to therapy.
Not studied or approved for use in women or children; safety in these groups is unknown.
Potential for additive hypotensive effects when combined with phosphodiesterase inhibitors like sildenafil.
Should not be used in patients with a history of prostate cancer without adequate evaluation.
Avoid abrupt dose changes without physician supervision.
WARNING: Do not attempt to double dose if a dose is missed to avoid hypotension.
Monitor for signs of hypersensitivity reactions including angioedema which require immediate medical attention.
Restricted use in patients with cardiovascular diseases where hypotension may exacerbate underlying condition.

Contraindication

Known hypersensitivity or allergic reaction to silodosin or any components of the formulation.
Severe renal impairment with creatinine clearance less than 30 mL/min.
Severe hepatic impairment.
Concurrent use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, or telithromycin.
Use in women and pediatric populations due to lack of safety and efficacy data.
Patients with history of orthostatic hypotension secondary to drug-induced causes.
Patients with anatomical urinary obstruction unrelated to BPH (e.g., prostate cancer without treatment).
Use in combination with other alpha-1 blockers without clinical justification and monitoring.
Patients with severe hypotension or shock.
Use during acute hypotensive episodes or unstable cardiovascular conditions.
Known severe allergy to alpha-1 adrenergic antagonists.
Patients who require surgical intervention for bladder outlet obstruction without prior medical management.
Contraindicated in patients with conditions predisposing to ejaculatory disturbances where the risk outweighs benefit.
Patients with volume depletion or dehydration conditions without correction.
Patients undergoing eye surgery who have not informed their ophthalmologist about silodosin use.

Drug Interactions

Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, telithromycin) significantly increases silodosin plasma concentrations, increasing risk for adverse effects.
Concomitant use with other alpha-1 blockers (alfuzosin, doxazosin, prazosin, tamsulosin, terazosin) may cause additive hypotensive effects and increase risk of dizziness and fainting.
Interaction with antihypertensive medications may potentiate blood pressure lowering, leading to symptomatic hypotension.
Phosphodiesterase-5 inhibitors (e.g., sildenafil) combined with silodosin can result in additive vasodilatory effects and increased risk of hypotension.
Use with diuretics ('water pills') may exacerbate hypotensive risk due to volume depletion.
Drugs altering gastrointestinal motility may affect silodosin absorption and efficacy.
Inhibitors or inducers of CYP3A4 can decrease or increase silodosin metabolism, necessitating dose adjustments.
Potential interaction with HIV or hepatitis C antiviral agents like lopinavir/ritonavir and boceprevir which are CYP3A4 inhibitors.
Co-administration with nefazodone, an antidepressant CYP3A4 inhibitor, can elevate silodosin exposure.
Concurrent use with anticoagulants or antiplatelet agents should be monitored for bleeding risk due to potential hypotension leading to falls.
Drugs causing miosis or affecting the autonomic nervous system may alter silodosin's effect on urinary symptoms.
Alcohol may potentiate hypotensive adverse effects and should be consumed cautiously.
Herbal supplements with alpha-blocking effects (e.g., yohimbine) may interact adversely.
Strong CYP3A4 inducers may reduce silodosin efficacy by increasing metabolism.
Close monitoring warranted when starting or stopping interacting medications concomitant with silodosin therapy.

Preparations Of The Drug

Rapaflo oral capsules available in 4 mg and 8 mg strengths.
Capsules designed for once-daily oral administration with a meal to improve absorption.
Capsule contents may be opened and mixed with cool, soft applesauce for patients with swallowing difficulties.
Supplied in blister packs or bottles with child-resistant caps to ensure stability and safety.
Stored at controlled room temperature between 20°C to 25°C (68°F to 77°F), protected from moisture, heat, and light.
Available as prescription-only medication indicated for benign prostatic hyperplasia.
Furnished with patient information leaflets outlining administration, precautions, and potential side effects.
Formulated with excipients that maintain capsule integrity and promote optimal dissolution in the gastrointestinal tract.
Packaging includes dosing instructions emphasizing once-daily intake and precautions regarding orthostatic hypotension.
Multiple manufacturers may produce generic formulations meeting FDA approval standards for silodosin.
Commercially available in various countries under the brand name Rapaflo and generic silodosin names.
Stable with a shelf life generally exceeding one year when stored under recommended conditions.
Not formulated for pediatric use or for administration via alternate routes such as intravenous or transdermal.
Provided in unit dose packaging for accurate dispensing and to reduce dosing errors.
Patient assistance programs may be available for branded formulations dependant on regional healthcare systems.